Granted Patent B2

US 9,314,473 · App. 14/802,060 · Granted Apr 19, 2016

Inventors: Randice Lisa Altschul (Cliffside Park, NJ); Neil David Theise (New York, NY); Myron Rapkin (Indianapolis, IN); Rebecca O'Brien (Shell Knob, MO)

Assignee: Pop Test Oncology Limited Liability Company

A61K31/58A61J1/10A61K9/08A61K9/10A61K9/107A61K31/337A61K45/06A61K47/10A61K47/26A61K47/34A61K47/42A61K47/44A61N5/1001B65D75/002B65D75/36B65D75/367C07J17/00

Abstract

Claims (9)

1. A pharmaceutical composition for treating treatment resistant prostate cancer, comprising:

a) therapeutically effective amounts of at least one androgen receptor antagonist selected from the group consisting of ARN-509, enzalutamide, ketonazole, abiraterone, abiraterone acetate, orteronel, and combinations thereof;

b) therapeutically effective amounts of the GCR (glucocorticoid receptor) antagonist ORG 34517; and

c) optionally, at least one pharmaceutically acceptable carrier.

2. A kit for treating treatment resistant prostate cancer comprising:

(a) therapeutically effective amounts of the GCR (glucocorticoid receptor) antagonist ORG 34517;

(b) therapeutically effective amounts of at least one androgen receptor antagonist selected from the group consisting of ARN-509, flutamide, enzalutamide, bicalutamide, ketonazole, abiraterone, abiraterone acetate, and combinations thereof;

(c) optionally, at least one pharmaceutically acceptable carrier; and

(d) at least one blister package; a lidded blister; a blister card or packet; a clamshell; an intravenous (IV) package, IV packet or IV container; a tray or a shrink wrap comprising the pharmaceutical composition of (a) and instructions for use of the pharmaceutical composition for treating treatment resistant prostate cancer.

Assignments (1)

Continuity (8)